Algemeen De software (inclusief de Boot ROM-code, ingebedde software en software van andere fabrikanten), de documentatie, de interfaces, het materiaal, de lettertypen en de gegevens bij je apparaat (“originele Apple software”), die kunnen ▇▇▇▇▇▇ bijgewerkt of vervangen door verbeterde functionaliteit, software- updates of systeemherstelsoftware van Apple (“Apple software-updates”), hetzij in “read only”- geheugen, hetzij op enig ander medium of in enige andere vorm (de originele Apple software en Apple software-updates ▇▇▇▇▇▇ gezamenlijk de “Apple software” genoemd), ▇▇▇▇▇▇ aan jou in licentie gegeven, niet verkocht, door Apple Inc. (“Apple”), uitsluitend voor gebruik onder de voorwaarden van deze licentie. Apple en licentiegevers van Apple behouden het eigendomsrecht met betrekking tot de Apple software en behouden zich alle rechten voor die niet uitdrukkelijk aan jou zijn toegekend. Je stemt ermee in dat de voorwaarden van deze licentie van toepassing zijn op elke app van Apple die mogelijk is ingebouwd op je apparaat, tenzij een dergelijke app een afzonderlijke licentie bevat, in ▇▇▇▇ geval je ermee instemt dat de voorwaarden van deze afzonderlijke licentie van toepassing zijn op je gebruik van de app.
Platby In consideration for the proper performance of the Study by Institutionin compliance with the terms and conditions of this Agreement, payments shall be made in accordance with the provisions set forth in Attachment A, with the last payment being made after the Site completes all its obligations hereunder, and IQVIA has received all properly completed CRFs and, if IQVIA requests, all other Confidential Information (as defined below. DrugDev will receive Site invoices and process payments unless otherwise agreed. Any queries regarding Institution invoices or payments should be directed to ▇▇▇▇▇▇▇ at the contact details outlined in Attachment A. V souvislosti s řádným plněním Studie Poskytovatelem, a to v souladu s podmínkami a ustanoveními této Smlouvy, budou poskytovány platby dle podmínek a ustanovení definovaných v Příloze A, přičemž poslední platba bude uskutečněna poté, co Místo provádění klinického hodnocení splní a dokončí veškeré závazky, jež mu vyplývají z této Smlouvy, a IQVIA obdrží veškeré řádně vyplněné CRF a, bude-li tak IQVIA vyžadovat, veškeré další Důvěrné informace (ve smyslu níže uvedené definice). Nebude-li ujednáno jinak, faktury bude Místo provádění klinického hodnocení zasílat společnosti DrugDev, která je bude proplácet. Veškeré dotazy ohledně faktur Místa provádění klinického hodnocení nebo plateb je třeba směřovat na společnost DrugDev, jejíž kontaktní údaje jsou uvedeny v Příloze A.
VOETSTOOTS The PROPERTY is sold: 8.1. Voetstoots in accordance with the Sectional Plan and the participation quota endorsed thereon with the opening of the Sectional Title Register, or as they are endorsed already, and any amendments or adjustments thereto from time to time in accordance with the terms of the Act and without any warranties express or implied, the SELLER shall not be liable for any patent or latent defects. Should the extent of the Section or of the PROPERTY differ from that which is contained in the title deed or sectional plan or any amendment thereto, the SELLER shall not be liable for any shortfall or be entitled to any compensation for any surplus. 8.2. Subject to all the conditions and Regulations of the Act. 8.3. The PURCHASER acknowledges that this is not a construction contract and that he is purchasing a completed unit. The PURCHASER shall not have the right to interfere in any way with the building operations of the SELLER’S employees. He shall also have no right to retention. This Clause is also applicable in the case of the bank holding back any retention amount out of its own accord or on request of the PURCHASER. 8.4. The SELLER undertakes to erect the unit according to the general building standards as set by Financial Institutions. The unit is be registered with the NHBRC. 8.5. Should a dispute arise or be declared, such dispute shall be resolved by an Arbitrator appointed by the Developer. The costs in respect thereof shall be borne by the unsuccessful party. Pending the outcome of the dispute, the PURCHASER shall be obliged to pay the outstanding amount to the Conveyancers who shall hold it in trust.
Attn ▇▇▇▇▇▇ ▇.
Managing Director 1. The Managing Director shall be appointed by the Board of Governors from among candidates having the nationality of an ESM Member, relevant international experience and a high level of competence in economic and financial matters. Whilst holding office, the Managing Director may not be a Governor or Director or an alternate of either. 2. The term of office of the Managing Director shall be five years. He or she may be re-appointed once. The Managing Director shall, however, cease to hold office when the Board of Governors so decides. 3. The Managing Director shall chair the meetings of the Board of Directors and shall participate in the meetings of the Board of Governors. 4. The Managing Director shall be chief of the staff of the ESM. He or she shall be responsible for organising, appointing and dismissing staff in accordance with staff rules to be adopted by the Board of Directors. 5. The Managing Director shall be the legal representative of the ESM and shall conduct, under the direction of the Board of Directors, the current business of the ESM.